Showing 719 results
-
Media Release /Entresto is the first and only therapy approved in the US to treat patients diagnosed with guideline-defined heart failure to include both those with heart failure with reduced ejection fraction (…
-
Media Release /Ligelizumab is the first treatment to receive FDA Breakthrough Therapy designation in chronic idiopathic urticaria (CIU) in patients with an inadequate response to H1 anthistamines1 Currently…
-
Media Release /
-
Media Release /The Committee voted 12 to 1 that the data presented support the use of Entresto in treatment of patients with heart failure with preserved ejection fraction (HFpEF) Potential Q1 2021 sNDA approval…
-
Media Release /
-
Media Release /
Novartis Kisqali® demonstrates nearly five years median overall survival in metastatic breast cancer
MONALEESA-7 median overall survival (OS) results reinforce Kisqali as the CDK4/6 inhibitor with unrivaled OS evidence1 Kisqali plus endocrine therapy had a median OS of nearly five years (58.7… -
Media Release /
-
Media Release /At 24 weeks, asciminib nearly doubled the major molecular response (MMR) rate compared to Bosulif® (bosutinib)*, in patients resistant to, or intolerant of, at least two prior tyrosine kinase…
-
Media Release /
-
Media Release /The Know Migraine Mission initiative seeks to challenge misconceptions and start new conversations about migraine Karamo Brown to connect directly with people affected by migraine to share…
